Knowing the rules is not enough to navigate regulatory compliance minutiae—you need to understand them like a regulator does.
Health Policy Associates (HPA) has built its reputation on this perspective, leveraging its expertise to guide clients through the intricate requirements of agencies like the Food and Drug Administration (FDA).
This philosophy stems from Founder Vincent Bucci, who brought invaluable insights from his time at Pfizer, where he tackled compliance challenges head-on. This expertise earned his newly founded consultancy an invitation to assist with the FDA’s Application Integrity Policy—a program addressing companies submitting misleading or falsified data.
HPA’s work involved examining nearly every aspect of a medical device or biotech company’s operations that contributed to regulatory submissions—clinical study protocols, electronic data capture (EDC) systems, standard operating procedures (SOP), quality management systems, interactions and manufacturing processes. Essentially, HPA scrutinized everything that could potentially cast a submission in a negative light from the FDA’s perspective. HPA is perhaps the only medical device consulting firm with services covering regulatory, clinical, quality systems and manufacturing assistance for companies of all sizes. For early-stage companies, HPA is truly a “one-stop” shop.
“The arrangement allowed us to build a unique relationship with the agency and gain insights into its culture and thought process. It also gave us a firsthand view of how companies encounter regulatory challenges. Once we identified these issues, our role was to develop and implement strategies to resolve them,” says Dan Howell, VP of business development.
Today, that foundational experience shapes HPA’s role as a trusted partner for biotechnology and medical device companies. From regulatory pre-submissions to complex filings like Investigational Device Exemptions (IDE), 510(k) premarket notifications and premarket Approvals (PMA), HPA ensures companies avoid costly missteps while building a foundation for long-term success.
The Roadmap to Regulatory Readiness
Effective preparation is a cornerstone of success in the life sciences industry, especially for small startup medical device companies, which comprise a significant portion of HPA’s client base. Operating on limited financial reserves, these companies face the dual pressures of innovation and efficiency. Shaving months and even years off development timelines to final product approval can conserve precious resources, minimize cash burns and keep them on course toward achieving their goals.
“There are numerous examples of companies that didn’t succeed simply because they ran out of money,” explains Howell. “If things take too long, investors get tired of writing checks. They may have been willing to cover the initial cost, but funding dries up when timelines slip.”
Bucci adds, “HPA takes great pride in its reputation for being extraordinarily efficient in implementing its programs across all of its services, especially clinical trial execution.”
HPA streamlines every step of the process. It begins with strategy, where clarity is king. HPA collaborates with companies to design regulatory roadmaps, engaging directly with the FDA to address testing requirements and gain buy-in on clinical trials. For early-stage companies, this often involves integrating strategies with available financial resources. Early alignment with the agency clarifies expectations, secures agreement on critical steps and significantly reduces risks. Confirming required testing and clinical trial protocols enables companies to establish realistic budgets and timelines. Armed with this level of detail, companies can confidently approach investors with clear, data-driven plans that inspire trust. For early-stage companies, it also develops strategies and approaches that work hand in hand with a company moving through various stages of financing.
One core part of HPA’s business recently has been the emergence of many companies outside the U.S. seeking FDA approval. HPA’s reputation and business reach have become increasingly global. Over half of its revenue now comes from U.S. companies seeking EC and Chinese approval and companies from outside the U.S. are looking to enter the American market. A significant advantage of working with these companies early in the process is the ability to generate a single data package across preclinical, clinical and manufacturing areas, which can be leveraged for approvals in multiple jurisdictions. This streamlined approach creates substantial value for companies navigating complex regulatory landscapes.
Working with a group like HPA allows companies to focus precisely on what needs to be done to get their product approved and to market. It guides clients in focusing on the most impactful steps that accelerate regulatory approval and drive long-term success. Time and resources are invested where they matter most. For example, some companies run animal tests funded by grants, but the data from these tests often fails to meet FDA or notified body requirements. The data might interest clinicians, but it holds no value for regulatory approval. HPA often sees this fault in academic-based medical device start-ups.
Once an intelligent strategy is validated, HPA transitions into action. Quality management systems are refined for companies with existing frameworks or developed from the ground up for those without. The result is regulatory compliance and a strong basis for preclinical testing. Labs are carefully selected, budgets are established upfront and protocols are reviewed to mitigate risks. Addressing regulatory concerns early creates a solid foundation for progression.
Next comes product development, where ideas take tangible form. For Class II and III devices, this phase demands rigorous validation and verification to ensure readiness for clinical trials. HPA’s expertise ensures that every requirement is met without wasted effort, positioning the product for success in the subsequent critical phase.
-
All of our senior people grew up in the industry. They’ve worked in our clients’ shoes, meaning they understand the daily challenges and nuances. This perspective eliminates the need for lengthy explanations, allowing clients to focus on efficiently bringing their product to market
Next comes product development, where ideas take tangible form. For Class II and III devices, this phase demands rigorous validation and verification to ensure readiness for clinical trials. HPA’s expertise ensures that every requirement is met without wasted effort, positioning the product for success in the subsequent critical phase.
Clinical trials mark a pivotal phase of the process. Acting as a full-service contract research organization (CRO), HPA manages trials from start to finish. This includes selecting trial sites, recruiting principal investigators and structuring contracts to align with protocols and budgets. In-house experts—biostatisticians, clinical research associates and medical writers—oversee every detail, ensuring trial outcomes align with regulatory requirements and support submission readiness. HPA is confident when it says no other firm executes a clinical trial as efficiently as HPA. “We save significant time and money by being the most efficient firm out there,” says Bucci.
By the time a device is ready for regulatory submission, HPA has laid the groundwork for success. “Over the years, we have developed a library of hundreds of Q-subs on all sorts of topics, giving us tremendous insight into a wide variety of preclinical and manufacturing issues, in addition to other questions,” says Bucci. Comprehensive applications, such as PMAs, 510(k)s, BLAs and Investigational New Drugs (IND), integrate data from testing, quality systems and manufacturing processes. These submissions are not just complete—they are strategically crafted to withstand scrutiny, reducing the risk of delays or additional queries from regulators.
“HPA’s value goes far beyond regulatory approval. For many clients, our journey extends into post-approval support, manufacturing scale-up and market readiness. By fostering long-term partnerships, we ensure continuity and trust, guiding companies through the entire lifecycle of their products,” adds Howell.
Teamwork that Stands the Test of Time
Many projects dating from early conception to regulatory approval span seven to 10 years and tracking the intricate details across regulatory, quality and clinical workflows can be a significant challenge for companies. HPA excels in this area, especially given its expertise in regulatory, preclinical, clinical and manufacturing areas. Thanks to its tiered structure and in-house collaboration model, every project is managed by the same project manager, clinical research associate and regulatory support team throughout the engagement. This consistency eliminates disruptions caused by personnel turnover, ensuring smooth progress from start to finish. Integrating all these functions within one organization efficiently allows for tremendous efficiency in time and costs.
The junior team handles the initial drafting and groundwork, the mid-tier management team refines the work into a near-final form and the senior team provides expert oversight, adding final touches before documents leave HPA. This layered approach ensures that every deliverable—an FDA submission, a National Medical Products Administration submission or a CE mark report— meets the highest standards while minimizing questions or delays for a faster, smoother approval process.
Collaboration at HPA extends beyond structured workflows. Regulatory, quality and clinical teams operate under one roof, allowing a transition between project phases. This integrated setup reduces delays, aligning every aspect of a project to promote efficiency. The overlapping expertise among teams creates precision and alignment that few can match so that no critical detail is overlooked.
“All of our senior people grew up in the industry. They’ve worked in our clients’ shoes, meaning they understand the daily challenges and nuances. This perspective eliminates the need for lengthy explanations, allowing clients to focus on efficiently bringing their product to market,” explains Howell.
Two Paths, One Market
The contrasting journeys of two European aesthetic device manufacturers offer a compelling case for the transformative impact of timely decisions and expert guidance. Both companies shared the goal of entering the U.S. market with their innovative products. But their paths could not have been more different.
Eighteen months ago, one company wasted no time. After contacting HPA, they signed a contract within a week. This decisive move set the wheels in motion. A comprehensive gap analysis of their data room and documentation aligned every detail with FDA requirements for their IDE application. Thanks to their quick action, clinical trials began without a hitch, keeping them firmly on track toward their U.S. market ambitions for their Class III device, which they achieved in record time.
The other company, however, hesitated. Despite their initial inquiry, they spent months deliberating, considering other consulting options and weighing their next move. Six months later, they opted for another provider that did not have HPA’s regulatory knowledge and strategic approach. Over two years later, they are still bogged down without even having submitted the IDE. The choice and the delay created obstacles that would prove challenging to overcome.
Fast-forward to today and the difference between the two is stark. The first company has completed one clinical trial, submitted its PMA application and is awaiting FDA approval. Another trial is already nearing completion, putting it just months away from U.S. market access.
Meanwhile, the second company has yet to secure IDE approval, so it has not even begun clinical trials. As a result, it is at least two years away from submitting its first PMA—more than three years behind Company A. “The second company has lost whatever value existed since they have fallen so far behind others that the market simply won’t be robust by the time they get there,” says Bucci.
“We have a strong history with the FDA because we know exactly what they’re looking for. We know how to position these companies strategically and we know how to write submissions in a way that’s much more acceptable to the FDA,” states Howell.
The case study serves as a reminder that hesitation can be costly in the evolving world of biotechnology and medical devices. Expert guidance is invaluable. With HPA as a trusted partner, companies can transform their bold ideas into market realities, confidently tackling challenges and seizing opportunities in an ever-evolving landscape. The message is clear—success favors those who prepare, act decisively and leverage expertise to move forward with clarity and purpose.
Choosing the Right Regulatory Services Partner
Medical device, biotechnology and biologics companies rarely fail because the science itself lacks promise. More often, programs lose momentum when the regulatory path is misunderstood too late in development. Companies may generate evidence that does not fully support the intended claims, design studies that drift from agency expectations or delay building quality systems until regulatory scrutiny is already underway. For executives selecting a regulatory services provider, the challenge is therefore much larger than choosing a firm that can prepare submissions. The right partner should help connect regulatory expectations with practical development planning, evidence strategy and business timing from the outset.
That pressure has become more visible across the healthcare sector. Funding conditions are tighter, review standards are more demanding and development timelines continue to stretch longer. Emerging companies are often forced to balance limited capital against the need to build credible data packages, while larger organizations face the complexity of global submissions, post-market obligations and cross-functional coordination across regulatory, clinical and quality teams. In either case, delays carry real business consequences. They affect launch schedules, investor confidence, operating plans and the overall credibility of the product strategy.
Strong regulatory support begins well before a filing is drafted. Experienced providers help companies define product classification, intended use claims, evidence requirements and likely review pathways early enough to influence budgets, testing plans and study design. That guidance can prevent companies from investing in work that adds scientific detail but little regulatory value. At the same time, effective advisors know when a development plan is becoming too lean. Reducing unnecessary work only helps if the resulting package still meets the standards regulators are expected to apply.
Agency interaction is another area where quality matters significantly. Communication with the FDA and other regulatory bodies should not be treated as a late-stage procedural step. Early engagement often helps companies confirm assumptions, identify testing expectations and address weaknesses while adjustments are still manageable. The best regulatory partners understand how to structure those discussions carefully by preparing focused briefing materials, framing the right questions and helping leadership interpret agency feedback within the context of the broader development strategy.
Execution discipline is often what separates capable consultants from true strategic partners. Regulatory submissions depend on clinical evidence, manufacturing readiness, quality systems and statistical analysis moving together in a coordinated way. When those functions become disconnected, inconsistencies and delays tend to follow. Strong regulatory teams help maintain continuity across long development timelines so that the scientific rationale, regulatory strategy and submission narrative remain aligned as programs evolve. That continuity becomes especially important during pivotal development stages, when executives need clear guidance on whether evidence is sufficient, where additional validation is necessary and which risks are worth taking.
Health Policy Associates stands out for organizations seeking regulatory support that stays closely connected to product development, clinical execution and quality readiness. The firm provides support across regulatory strategy, Pre-IDE and pre-submission meetings, 510(k)s, IDEs, PMAs, BLAs, CE-related documentation and global market applications, while also offering expertise in design controls, verification and validation, audit preparation, biostatistics, clinical strategy and medical writing. What makes the model compelling is the way these functions appear integrated rather than siloed. For healthcare executives managing device, pharmaceutical or biologics programs, Health Policy Associates represents a strong option when regulatory planning needs to remain practical, coordinated and aligned with reviewer expectations throughout development.
...Read more
Regulatory Services Info
Q1
What has positioned Health Policy Associates among Top Regulatory Services Providers?
Decades of FDA-focused consulting expertise and a regulator-centered advisory approach have helped Health Policy Associates gain recognition among Top Regulatory Services Providers. The company supports medical device, biotechnology and pharmaceutical organizations through regulatory strategy, clinical trial support, quality systems consulting and manufacturing guidance. Its experience working on FDA Application Integrity Policy initiatives gave the company valuable insight into how regulators evaluate submissions and compliance risks. This perspective has strengthened Health Policy Associates’ position within regulatory services providers.
Q2
How does Health Policy Associates differentiate its regulatory consulting approach?
Health Policy Associates emphasizes regulatory preparation through the lens of agency expectations rather than standard documentation support alone. The company structures its regulatory services providers capabilities around integrated consulting that combines regulatory strategy, clinical operations, quality systems and manufacturing expertise within one organization. Its teams help clients address pre-submissions, IDEs, PMAs, 510(k)s and other regulatory pathways with a focus on minimizing delays and reducing unnecessary costs. This highly coordinated consulting model gives Health Policy Associates a differentiated presence within regulatory services providers.
Q3
How does the company support product development and regulatory readiness?
Successful regulatory outcomes depend on early planning, accurate testing strategies and consistent execution. Health Policy Associates supports regulatory services providers through roadmap development, FDA engagement support, quality system implementation and clinical trial management designed to strengthen approval readiness. Its consulting process helps organizations align timelines, budgets and testing protocols with regulatory expectations before major investments are made. By identifying compliance gaps early, the company contributes to more efficient product development and regulatory progression.
Q4
What role does expertise play in Health Policy Associates’ services?
Industry experience remains central to the company’s consulting model. Health Policy Associates applies regulatory, clinical and manufacturing expertise to strengthen regulatory services providers across complex healthcare and medical technology environments. Many senior team members previously worked within the industries they now support, which helps the company understand practical operational challenges alongside regulatory requirements. This expertise-driven structure enables Health Policy Associates to provide more informed guidance throughout the product development lifecycle.
Q5
How do regulatory services providers create value through Health Policy Associates?
Regulatory value depends on reducing delays, improving submission quality and strengthening development efficiency. Health Policy Associates delivers regulatory services providers support that helps organizations improve clinical trial execution, streamline regulatory documentation and maintain stronger compliance alignment. Its integrated consulting structure also contributes to more efficient collaboration between regulatory, clinical and quality teams throughout development activities. This balance between strategic planning and execution support increases the long-term value of the company’s services.
Q6
Why is Health Policy Associates relevant to the future of regulatory consulting?
Life sciences organizations continue to face growing regulatory complexity, expanding global compliance expectations and increasing pressure to accelerate approvals. Health Policy Associates contributes to this evolving landscape through regulatory services providers focused on FDA strategy, integrated consulting and efficient clinical execution. Its emphasis on practical regulatory readiness and long-term client partnerships aligns with industry priorities surrounding compliance efficiency and product commercialization. As healthcare technologies become increasingly sophisticated, the company remains relevant to the future of regulatory consulting and life sciences development.
